{"protocolSection": {"identificationModule": {"nctId": "NCT02002702", "orgStudyIdInfo": {"id": "CRLX030A1201"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients", "officialTitle": "A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of Serelaxin When Added to Standard Therapy in Japanese Acute Heart Failure Patients"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-01"}, "primaryCompletionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-12-01", "studyFirstSubmitQcDate": "2013-12-01", "studyFirstPostDateStruct": {"date": "2013-12-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-08-03", "resultsFirstSubmitQcDate": "2015-09-11", "resultsFirstPostDateStruct": {"date": "2015-10-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-11", "lastUpdatePostDateStruct": {"date": "2015-10-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a multicenter, randomized, double-blind, placebo-controlled study to assess safety, tolerability and pharmacokinetics and to explore efficacy of IV infusion of 10 \u00b5g/kg/day and 30 \u00b5g/kg/day serelaxin for 48 hours compared to placebo, when added to the standard therapy, in approximately 45 Japanese AHF patients."}, "conditionsModule": {"conditions": ["Acute Heart Failure"], "keywords": ["Acute heart failure (AHF),", "Japanese,", "Safety and tolerability, Pharmacokinetics,", "Renal Impairment"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 46, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Serelaxin 10 mcg/kg/Day", "type": "EXPERIMENTAL", "description": "Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.", "interventionNames": ["Drug: Serelaxin"]}, {"label": "Serelaxin 30 mcg/kg/Day", "type": "EXPERIMENTAL", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.", "interventionNames": ["Drug: Serelaxin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Serelaxin", "description": "Intravenous infusion", "armGroupLabels": ["Serelaxin 10 mcg/kg/Day", "Serelaxin 30 mcg/kg/Day"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and Additional Therapy", "description": "AEs were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards. AEs leading to discontinuations, or requiring dose adjustment or interruptions and additional therapy were assessed.", "timeFrame": "From start of study treatment up to Day 5 (for AEs); From start of study treatment up to Day 14 (for SAEs)"}, {"measure": "Maximum Plasma Concentration (Cmax) of Serelaxin", "description": "Maximum plasma concentration (Cmax) was defined as the peak level of serelaxin, derived from plasma concentration-time data, using a non-compartmental model approach.", "timeFrame": "Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)"}, {"measure": "Weight Adjusted Clearance (CL) of Serelaxin", "description": "Weight adjusted clearance (CL) was defined as the total body clearance of serelaxin after drug administration. CL was calculated as nominal infusion rate divided by Css, using a non-compartmental model approach.", "timeFrame": "Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)"}, {"measure": "Concentration at Steady-state (Css) of Serelaxin", "description": "Concentration at steady-state (Css) was defined as concentration at the state of equilibrium obtained at the end of a certain number of administrations. Css of serelaxin in plasma was calculated by using a non-compartmental model approach.", "timeFrame": "Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Area Under the Curve (AUC) for Systolic Blood Pressure (SBP) Through 48 Hours of Infusion at Day 5", "description": "The area under the curve (AUC) was defined as area under the plasma concentration-time curve from time zero to time of the last time point with measurable concentration, calculated by a trapezoidal method. Systolic blood pressure was measured using a calibrated standard sphygmomanometer after the subject remained in sitting position for 3 minutes at clinic during the visit. Sample collected at: Baseline; 30 \\& 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during 48 hours of study drug infusion; every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5 or discharge.\n\nAUC for SBP is standardized by dividing by the length of respective time ranges.", "timeFrame": "Baseline, 48 hours, Day 5"}, {"measure": "Change From Baseline in Aldosterone Levels Through Day 14", "description": "Aldosterone biomarker was used to assess the effect of serelaxinin on fluid retention. Geometric means of the ratio of post-Baseline values to baseline values of aldosterone was calculated by treatment for the full analysis set.", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14"}, {"measure": "Change From Baseline in Cystatin-C Levels Through Day 14", "description": "Cystatin-C biomarker was used to assess the effect of serelaxinin on worsening of renal function. Geometric means of the ratio of post-Baseline values to baseline values of Cystatin-C was calculated by treatment for the full analysis set.", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14"}, {"measure": "Change From Baseline in High Sensitivity Troponin-T Levels Through Day 14", "description": "High sensitivity Troponin-T biomarker was used to assess the effect of serelaxin on myocardial damage. Geometric means of the ratio of post-Baseline values to baseline values of high sensitivity troponin-t was calculated by treatment for the full analysis set.", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14"}, {"measure": "Change From Baseline in NT-proBNP Levels Through Day 14", "description": "NT-proBNP biomarker was used to assess the effect of serelaxinin on degree of cardiac wall stress and congestion. Geometric means of the ratio of post-Baseline values to baseline values of NT-proBNP was calculated by treatment for the full analysis set.", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14"}, {"measure": "Change From Baseline in Neutrophil Gelatinase-asc Lipocalin (NGAL) Levels Through Day 14", "description": "Neutrophil gelatinase-asc lipocalin (NGAL) biomarker was used to assess the effect of serelaxin on kidney function. Geometric means of the ratio of post-Baseline values to baseline values of NGAL was calculated by treatment for the full analysis set.", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* Written informed consent must be obtained before any study-specific assessment is performed.\n* Male or female \u226520 years of age, with body weight \u226530 kg and \u2264160 kg\n* Hospitalized for AHF; AHF is defined as including all of the followings measured at any time between presentation (including the emergency department) and the end of screening:\n* Dyspnea at rest or with minimal exertion\n* Pulmonary congestion on chest radiograph\n* BNP \u2265350 pg/mL or NT-proBNP \u22651,400 pg/mL\n* SBP \u2265125 mmHg at the start and at the end of screening\n* Able to be randomized within 16 hours from presentation to the hospital, including the emergency department\n* Received intravenous (IV) furosemide of at least 40 mg (or equivalent) at any time between presentation (this include outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute heart failure (HF) episode.\n* Impaired renal function defined as an estimated glomerular filtration rate (eGFR) between presentation and randomization of \u2265 25 and\u2264 75 mL/min/1.73 m2, calculated using the Japanese formula\n\nKey Exclusion Criteria:\n\n* Dyspnea primarily due to non-cardiac causes\n* Temperature \\>38.5\u00b0C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment\n* Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment.\n* AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate \\<45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of \\>130 beats per minute.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Seto-city", "state": "Aichi", "zip": "489-8642", "country": "Japan", "geoPoint": {"lat": 35.23333, "lon": 137.1}}, {"facility": "Novartis Investigative Site", "city": "Fukuoka-city", "state": "Fukuoka", "zip": "810-0001", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Novartis Investigative Site", "city": "Iizuka-city", "state": "Fukuoka", "zip": "820-8505", "country": "Japan", "geoPoint": {"lat": 33.63654, "lon": 130.68678}}, {"facility": "Novartis Investigative Site", "city": "Hiroshima-city", "state": "Hiroshima", "zip": "730-8518", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Novartis Investigative Site", "city": "Amagasaki-city", "state": "Hyogo", "zip": "660-8550", "country": "Japan", "geoPoint": {"lat": 34.71667, "lon": 135.41667}}, {"facility": "Novartis Investigative Site", "city": "Higashiibaraki-gun", "state": "Ibaraki", "zip": "311-3193", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Kanazawa", "state": "Ishikawa", "zip": "920-8650", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Novartis Investigative Site", "city": "Kawasaki-city", "state": "Kanagawa", "zip": "211-8533", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Novartis Investigative Site", "city": "Yokohama-city", "state": "Kanagawa", "zip": "231-8682", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Novartis Investigative Site", "city": "Sendai-city", "state": "Miyagi", "zip": "981-3107", "country": "Japan", "geoPoint": {"lat": 38.26667, "lon": 140.86667}}, {"facility": "Novartis Investigative Site", "city": "Ueda-city", "state": "Nagano", "zip": "386-8610", "country": "Japan", "geoPoint": {"lat": 36.40265, "lon": 138.28161}}, {"facility": "Novartis Investigative Site", "city": "Osaka-city", "state": "Osaka", "zip": "534-0021", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Novartis Investigative Site", "city": "Sayama-city", "state": "Saitama", "zip": "350-1323", "country": "Japan", "geoPoint": {"lat": 35.85295, "lon": 139.41212}}, {"facility": "Novartis Investigative Site", "city": "Komatsushima-city", "state": "Tokushima", "zip": "773-8502", "country": "Japan"}, {"facility": "Novartis Investigative Site", "city": "Itabashi-ku", "state": "Tokyo", "zip": "173-8610", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The study was conducted at 15 centers in Japan.", "groups": [{"id": "FG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "FG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "FG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "15"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The analysis was performed on safety population defined as all randomized participants received any amount of study drug and had at least one post-baseline safety assessment.", "groups": [{"id": "BG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "BG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "BG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "46"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "70.2", "spread": "11.77"}, {"groupId": "BG001", "value": "79.7", "spread": "9.01"}, {"groupId": "BG002", "value": "76.4", "spread": "12.08"}, {"groupId": "BG003", "value": "75.3", "spread": "11.54"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "10"}]}]}, {"title": "\u2265 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "36"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "12"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "34"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and Additional Therapy", "description": "AEs were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards. AEs leading to discontinuations, or requiring dose adjustment or interruptions and additional therapy were assessed.", "populationDescription": "The analysis was performed on the safety population, defined as all participants who received at least one dose of study treatment and had at least one post-baseline assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From start of study treatment up to Day 5 (for AEs); From start of study treatment up to Day 14 (for SAEs)", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Discontinuation due to AE(s)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Discontinuation due to SAE(s)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "AEs requiring dose adjustment or interruption", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "AEs requiring additional therapy", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "AEs related to study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Maximum Plasma Concentration (Cmax) of Serelaxin", "description": "Maximum plasma concentration (Cmax) was defined as the peak level of serelaxin, derived from plasma concentration-time data, using a non-compartmental model approach.", "populationDescription": "The analysis was performed in the pharmacokinetic (PK) set, defined as all participants who received study treatment and had at least one evaluable PK parameter data. Here, \"Number of participants analyzed\" signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "nanogram(s)/milliliter (ng/mL)", "timeFrame": "Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.01", "spread": "2.07"}, {"groupId": "OG001", "value": "19.2", "spread": "4.69"}]}]}]}, {"type": "PRIMARY", "title": "Weight Adjusted Clearance (CL) of Serelaxin", "description": "Weight adjusted clearance (CL) was defined as the total body clearance of serelaxin after drug administration. CL was calculated as nominal infusion rate divided by Css, using a non-compartmental model approach.", "populationDescription": "The analysis was performed in the PK population. Here, \"Number of participants analyzed\" signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/hr/kg", "timeFrame": "Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "56.8", "spread": "15.4"}, {"groupId": "OG001", "value": "70.2", "spread": "23.2"}]}]}]}, {"type": "PRIMARY", "title": "Concentration at Steady-state (Css) of Serelaxin", "description": "Concentration at steady-state (Css) was defined as concentration at the state of equilibrium obtained at the end of a certain number of administrations. Css of serelaxin in plasma was calculated by using a non-compartmental model approach.", "populationDescription": "The analysis was performed in the PK population. Here, \"Number of participants analyzed\" signifies participants evaluable for this PK parameter at the specified time points for each arm, respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline (pre-dose), 1, 2, 24, 48, 49, 52 and 56 hours (post-dose)", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "8"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.81", "spread": "1.96"}, {"groupId": "OG001", "value": "19.1", "spread": "4.61"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Area Under the Curve (AUC) for Systolic Blood Pressure (SBP) Through 48 Hours of Infusion at Day 5", "description": "The area under the curve (AUC) was defined as area under the plasma concentration-time curve from time zero to time of the last time point with measurable concentration, calculated by a trapezoidal method. Systolic blood pressure was measured using a calibrated standard sphygmomanometer after the subject remained in sitting position for 3 minutes at clinic during the visit. Sample collected at: Baseline; 30 \\& 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during 48 hours of study drug infusion; every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5 or discharge.\n\nAUC for SBP is standardized by dividing by the length of respective time ranges.", "populationDescription": "The analysis was performed in the full analysis set (FAS) population, defined as all participants who were randomized in the study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, 48 hours, Day 5", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "48 hours", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.21", "spread": "2.903"}, {"groupId": "OG001", "value": "-18.6", "spread": "3.018"}, {"groupId": "OG002", "value": "-10.88", "spread": "3.018"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.79", "spread": "2.761"}, {"groupId": "OG001", "value": "-22.14", "spread": "2.871"}, {"groupId": "OG002", "value": "-14.77", "spread": "2.871"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Aldosterone Levels Through Day 14", "description": "Aldosterone biomarker was used to assess the effect of serelaxinin on fluid retention. Geometric means of the ratio of post-Baseline values to baseline values of aldosterone was calculated by treatment for the full analysis set.", "populationDescription": "The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.985", "lowerLimit": "0.7636", "upperLimit": "1.2717"}, {"groupId": "OG001", "value": "0.816", "lowerLimit": "0.6118", "upperLimit": "1.0897"}, {"groupId": "OG002", "value": "0.791", "lowerLimit": "0.6374", "upperLimit": "0.9825"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.975", "lowerLimit": "0.7492", "upperLimit": "1.2685"}, {"groupId": "OG001", "value": "0.721", "lowerLimit": "0.5195", "upperLimit": "0.9999"}, {"groupId": "OG002", "value": "0.911", "lowerLimit": "0.7141", "upperLimit": "1.1620"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.895", "lowerLimit": "0.6327", "upperLimit": "1.2656"}, {"groupId": "OG001", "value": "0.825", "lowerLimit": "0.6468", "upperLimit": "1.0531"}, {"groupId": "OG002", "value": "0.816", "lowerLimit": "0.5352", "upperLimit": "1.2452"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.510", "lowerLimit": "0.9934", "upperLimit": "2.2962"}, {"groupId": "OG001", "value": "1.114", "lowerLimit": "0.7983", "upperLimit": "1.5555"}, {"groupId": "OG002", "value": "1.179", "lowerLimit": "0.8337", "upperLimit": "1.6661"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Cystatin-C Levels Through Day 14", "description": "Cystatin-C biomarker was used to assess the effect of serelaxinin on worsening of renal function. Geometric means of the ratio of post-Baseline values to baseline values of Cystatin-C was calculated by treatment for the full analysis set.", "populationDescription": "The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.921", "lowerLimit": "0.8863", "upperLimit": "0.9565"}, {"groupId": "OG001", "value": "0.988", "lowerLimit": "0.9213", "upperLimit": "1.0598"}, {"groupId": "OG002", "value": "0.985", "lowerLimit": "0.9291", "upperLimit": "1.0450"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.930", "lowerLimit": "0.8736", "upperLimit": "0.9900"}, {"groupId": "OG001", "value": "0.852", "lowerLimit": "0.6465", "upperLimit": "1.1236"}, {"groupId": "OG002", "value": "0.965", "lowerLimit": "0.9002", "upperLimit": "1.0346"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.062", "lowerLimit": "0.9898", "upperLimit": "1.1384"}, {"groupId": "OG001", "value": "1.115", "lowerLimit": "1.0207", "upperLimit": "1.2178"}, {"groupId": "OG002", "value": "1.038", "lowerLimit": "0.9627", "upperLimit": "1.1194"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.195", "lowerLimit": "1.0154", "upperLimit": "1.4057"}, {"groupId": "OG001", "value": "1.136", "lowerLimit": "1.0348", "upperLimit": "1.2472"}, {"groupId": "OG002", "value": "1.125", "lowerLimit": "1.0313", "upperLimit": "1.2271"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in High Sensitivity Troponin-T Levels Through Day 14", "description": "High sensitivity Troponin-T biomarker was used to assess the effect of serelaxin on myocardial damage. Geometric means of the ratio of post-Baseline values to baseline values of high sensitivity troponin-t was calculated by treatment for the full analysis set.", "populationDescription": "The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.899", "lowerLimit": "0.7598", "upperLimit": "1.0643"}, {"groupId": "OG001", "value": "1.060", "lowerLimit": "0.8932", "upperLimit": "1.2572"}, {"groupId": "OG002", "value": "0.956", "lowerLimit": "0.8652", "upperLimit": "1.0559"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.856", "lowerLimit": "0.6935", "upperLimit": "1.0553"}, {"groupId": "OG001", "value": "1.040", "lowerLimit": "0.8514", "upperLimit": "1.2714"}, {"groupId": "OG002", "value": "0.894", "lowerLimit": "0.7650", "upperLimit": "1.0442"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.849", "lowerLimit": "0.5984", "upperLimit": "1.2044"}, {"groupId": "OG001", "value": "0.972", "lowerLimit": "0.7779", "upperLimit": "1.2151"}, {"groupId": "OG002", "value": "0.779", "lowerLimit": "0.5250", "upperLimit": "1.1572"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.820", "lowerLimit": "0.5729", "upperLimit": "1.1730"}, {"groupId": "OG001", "value": "0.813", "lowerLimit": "0.4480", "upperLimit": "1.4748"}, {"groupId": "OG002", "value": "0.685", "lowerLimit": "0.4652", "upperLimit": "1.0093"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in NT-proBNP Levels Through Day 14", "description": "NT-proBNP biomarker was used to assess the effect of serelaxinin on degree of cardiac wall stress and congestion. Geometric means of the ratio of post-Baseline values to baseline values of NT-proBNP was calculated by treatment for the full analysis set.", "populationDescription": "The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.585", "lowerLimit": "0.4356", "upperLimit": "0.7865"}, {"groupId": "OG001", "value": "0.646", "lowerLimit": "0.5146", "upperLimit": "0.8115"}, {"groupId": "OG002", "value": "0.673", "lowerLimit": "0.5416", "upperLimit": "0.8363"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.492", "lowerLimit": "0.3421", "upperLimit": "0.7076"}, {"groupId": "OG001", "value": "0.451", "lowerLimit": "0.3271", "upperLimit": "0.6210"}, {"groupId": "OG002", "value": "0.581", "lowerLimit": "0.4410", "upperLimit": "0.7656"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.388", "lowerLimit": "0.2502", "upperLimit": "0.6028"}, {"groupId": "OG001", "value": "0.386", "lowerLimit": "0.2575", "upperLimit": "0.5796"}, {"groupId": "OG002", "value": "0.526", "lowerLimit": "0.3685", "upperLimit": "0.7503"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.295", "lowerLimit": "0.1649", "upperLimit": "0.5293"}, {"groupId": "OG001", "value": "0.419", "lowerLimit": "0.2621", "upperLimit": "0.6691"}, {"groupId": "OG002", "value": "0.277", "lowerLimit": "0.1875", "upperLimit": "0.4079"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Neutrophil Gelatinase-asc Lipocalin (NGAL) Levels Through Day 14", "description": "Neutrophil gelatinase-asc lipocalin (NGAL) biomarker was used to assess the effect of serelaxin on kidney function. Geometric means of the ratio of post-Baseline values to baseline values of NGAL was calculated by treatment for the full analysis set.", "populationDescription": "The analysis was performed in the FAS population. Only participants with a value at both baseline and the post-dose time point were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Ratio", "timeFrame": "Baseline, Day 1, Day 2, Day 5, Day 14", "groups": [{"id": "OG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours."}, {"id": "OG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours."}, {"id": "OG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "15"}]}], "classes": [{"title": "Day 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.011", "lowerLimit": "0.8911", "upperLimit": "1.1478"}, {"groupId": "OG001", "value": "1.083", "lowerLimit": "0.9025", "upperLimit": "1.2996"}, {"groupId": "OG002", "value": "1.054", "lowerLimit": "0.9574", "upperLimit": "1.1613"}]}]}, {"title": "Day 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.929", "lowerLimit": "0.8443", "upperLimit": "1.0229"}, {"groupId": "OG001", "value": "1.172", "lowerLimit": "0.9994", "upperLimit": "1.3736"}, {"groupId": "OG002", "value": "1.099", "lowerLimit": "0.9866", "upperLimit": "1.2236"}]}]}, {"title": "Day 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.129", "lowerLimit": "1.0145", "upperLimit": "1.2560"}, {"groupId": "OG001", "value": "1.238", "lowerLimit": "1.0139", "upperLimit": "1.5114"}, {"groupId": "OG002", "value": "1.135", "lowerLimit": "1.0141", "upperLimit": "1.2698"}]}]}, {"title": "Day 14", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.434", "lowerLimit": "1.1760", "upperLimit": "1.7489"}, {"groupId": "OG001", "value": "1.520", "lowerLimit": "1.3214", "upperLimit": "1.7485"}, {"groupId": "OG002", "value": "1.433", "lowerLimit": "1.1793", "upperLimit": "1.7401"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit", "eventGroups": [{"id": "EG000", "title": "Serelaxin 10 mcg/kg/Day", "description": "Participants received 10 micrograms/kilogram/day (mcg/kg/day) serelaxin as continuous intravenous (i.v.) infusion for 48 hours.", "seriousNumAffected": 1, "seriousNumAtRisk": 16, "otherNumAffected": 10, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Serelaxin 30 mcg/kg/Day", "description": "Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.", "seriousNumAffected": 3, "seriousNumAtRisk": 15, "otherNumAffected": 9, "otherNumAtRisk": 15}, {"id": "EG002", "title": "Placebo", "description": "Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.", "seriousNumAffected": 0, "seriousNumAtRisk": 15, "otherNumAffected": 9, "otherNumAtRisk": 15}], "seriousEvents": [{"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "CARDIAC FAILURE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "CARDIAC FAILURE CONGESTIVE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "CORONARY ARTERY STENOSIS", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "VENTRICULAR TACHYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "INTESTINAL ISCHAEMIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "MULTI-ORGAN FAILURE", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "GASTRIC CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "METASTASES TO LIVER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "METASTASES TO LYMPH NODES", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "METASTASES TO PERITONEUM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "OESOPHAGEAL CARCINOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}], "otherEvents": [{"term": "ANAEMIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "IRON DEFICIENCY ANAEMIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "CARDIAC FAILURE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 15}]}, {"term": "CARDIAC FAILURE CONGESTIVE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "VENTRICULAR EXTRASYSTOLES", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "VENTRICULAR TACHYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "CONSTIPATION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "INFUSION SITE PAIN", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "HYPERBILIRUBINAEMIA", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "BACTERIAL INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "BLOOD PRESSURE DECREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "BLOOD PRESSURE SYSTOLIC DECREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "PLATELET COUNT DECREASED", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "DEHYDRATION", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "HYPOGLYCAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "HYPOKALAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 15}]}, {"term": "HYPONATRAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "DELIRIUM", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "INSOMNIA", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "RESTLESSNESS", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "HAEMATURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "RENAL IMPAIRMENT", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "GENITAL PAIN", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "EPISTAXIS", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "DERMATITIS CONTACT", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "ERYTHEMA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 15}]}, {"term": "PSORIASIS", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}, {"term": "VASCULITIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 15}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 15}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single--site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 -778 -8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M26718", "name": "Renal Insufficiency", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}